title: New antiepileptic medication linked to blue discoloration of the skin and eyes.
abstract: Ezogabine is an antiepileptic medication approved in June 2011 by the US Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures. Minimal drug interactions and a novel mechanism of action made ezogabine an appealing new treatment option. However, adverse effects reported during clinical trials and following drug approval have been alarming. A Risk Evaluation Mitigation Strategy (REMS) program has been established for urinary retention. A safety alert was published in April 2013 warning ezogabine may cause retinal pigment abnormalities and/or blue-gray discoloration, most notably on or near the lips, nail beds, sclera and conjunctiva with long-term use. In October 2013, the FDA announced a formal label change to ezogabine to include a black boxed warning emphasizing the previously reported warnings of eye and skin discoloration and permanent vision changes. Given the unknown nature of the pathophysiology, consequences and potential for reversibility of these effects, GlaxoSmithKline and the FDA have published recommendations for patients currently receiving ezogabine. Further data from published case reports and long-term safety trials in the future may lend additional insight into these concerning effects.
authors: Department of Pharmacy Mayo Clinic, 200 First Street SW Rochester Minnesota 55905, USA.
authors: Sarah
authors: S
authors: Clark
authors: Glendale Adventist Medical Center Department of Pharmaceutical Sciences 1509 Wilson Terrace Glendale, CA 91206, USA.
authors: Alexandra
authors: A
authors: Antell
authors: Department of Pharmacy Mayo Clinic 200 First Street SW Rochester, MN 55905.
authors: Kimberly
authors: K
authors: Kaufman
keywords: antiepilepsy medication; ezogabine; seizure; skin discoloration
references: Expert Opin Drug Discov. 2013 Nov;8(11):1429-37
references: 24053653
references: Epilepsy Curr. 2012 Jan;12(1):27-8
references: 22368525
references: Acta Dermatovenerol Croat. 2009;17(2):123-6
references: 19595269
references: Epilepsia. 2005 Apr;46(4):470-2
references: 15816939
references: Epilepsia. 2012 Mar;53(3):412-24
references: 22220513
references: Hautarzt. 1996 Dec;47(12):930-1
references: 9081941
references: Epilepsy Curr. 2011 May;11(3):75-8
references: 21686305
references: Epilepsy Res. 2012 Nov;102(1-2):117-21
references: 22771137
references: Epilepsia. 2001 Sep;42(9):1212-8
references: 11580774
references: Br J Dermatol. 1996 Aug;135(2):314-6
references: 8881683
references: Epilepsy Res. 2013 Nov;107(1-2):138-45
references: 24094693
references: Neurology. 2011 May 3;76(18):1555-63
references: 21451152
references: Neurology. 2007 Apr 10;68(15):1197-204
references: 17420403
references: Br J Pharmacol. 2013 Jan;168(1):19-27
references: 22880633
references: Drugs Today (Barc). 2010 Nov;46(11):815-22
references: 21225020
references: Pflugers Arch. 2010 Jul;460(2):277-88
references: 20401729
references: Neurology. 2010 Nov 16;75(20):1817-24
references: 20944074
references: Epilepsia. 2010 Apr;51(4):676-85
references: 20196795
references: Am J Ophthalmol. 1998 Mar;125(3):396-7
references: 9512163
references: Curr Clin Pharmacol. 2014 May;9(2):148-56
references: 24219007
references: Fed Regist. 2011 Dec 15;76(241):77895-99
references: 22175093
references: Curr Clin Pharmacol. 2013 Nov;8(4):319-31
references: 23342983
references: Mini Rev Med Chem. 2013 Apr 1;13(5):697-705
references: 22931529
references: Br J Dermatol. 1993 Aug;129(2):158-62
references: 7654575
references: J Urol. 2004 Nov;172(5 Pt 1):2054-8
references: 15540788
references: JAMA Dermatol. 2014 Sep;150(9):984-9
references: 25006968
references: PLoS One. 2013 Sep 20;8(9):e75875
references: 24073284
references: Epilepsia. 2007;48 Suppl 1:3-7
references: 17316406
references: Pflugers Arch. 2013 Sep;465(9):1371-81
references: 23592175
references: Clin Ther. 2013 Jan;35(1):87-93
references: 23328270